1️⃣ Angelini bought its U.S. rare-disease platform
Angelini agreed to buy Catalyst for $31.50 per share in cash, about $4.1B in equity value, with closing expected in Q3 2026. Catalyst brings Firdapse, Agamree and U.S. Fycompa rights.
💡 Why it matters
This is not discovery risk. Angelini is buying U.S. commercial rare-disease infrastructure and a neurology revenue base in one step.
☕ Coffee talk
After Catalyst, how many European rare-disease buyers can still wait outside the U.S.?
2️⃣ Entrada kept EEV-PMO alive, barely
Entrada reported Cohort 1 data for ENTR-601-44 in DMD: no serious AEs, normal kidney markers, a 2.36% dystrophin increase over 4.00% baseline, and significant Time to Rise velocity versus placebo.
💡 Why it matters
The readout keeps EEV-PMO in play, but low dystrophin makes Cohort 2 at 12 mg/kg the real platform proof.
☕ Coffee talk
Are investors buying the Time to Rise signal, or waiting for 12 mg/kg to do the real work?
3️⃣ GSK paid for an obesity-adjacent RNAi option
SiranBio licensed SA030 to GSK outside Greater China for an upfront fee and up to $1.005B in milestones. The phase 1 siRNA targets ALK7 for abdominal fat and cardiometabolic risk.
💡 Why it matters
GSK is adding an obesity-adjacent RNAi shot without joining the GLP-1 race. The bet is fat distribution, not headline weight loss.
☕ Coffee talk
Does ALK7 become a combo asset, or just another careful way to avoid saying obesity?